36results about How to "Good correlation between in vitro and in vivo" patented technology

A medicine core composition used for low solubility active medicine controlling release administration is provided in the present invention, wherein, at least comprising medicine-containing layer and boosting layer, the medicine-containing layer comprises low solubility active medicine and hydrophilic polymer carrier, the boosting layer at least comprises penetration enhancing polymer, insoluble polymer and osmotic pressure promoter; a osmotic pump containing the medicine core composition is also provided in the present invention, wherein also comprising semi-transparent material film coating outer of the medicine core; the medicine core composition of the present invention can controlled speed release medicine, leading the preparation containing the medicine core to achieve aim of administration one time every day, that is about in 24 hours to release active medicine.

The invention belongs to the technical field of medicinal preparations, and in particular relates to a self-assembled composite membrane controlled sustained-release preparation and a preparation method thereof. The self-assembled composite membrane controlled sustained-release preparation comprises 2.5 to 67 percent of medicament, 12 to 76 percent of cationic polymer, 12 to 76 percent of anionic polymer and the balance of other auxiliary materials. Through the traditional process, matrix tablets or granules are prepared from polymers such as chitosan, sodium alga acid, carrageenan, sodium carboxymethylcellulose and the like with different charges; and in the releasing process, based on physiology pH change of a human body, two or more polymers with the different charges are reacted with each other to form an insoluble composite membrane on the surface of the tablet, and the matrix system is automatically converted into self-assembled composite membrane controlled sustained-release tablets or granules. The method can prepare medicaments with good controlled sustained-release effect by a simple process.

The invention belongs to the technical field of pharmaceutical preparations and discloses a paliperidone bi-layer osmotic pump progressively-increased controlled release tablet and a preparation method thereof. The osmotic pump preparation comprises a tablet core and a semipermeable coating film, wherein the tablet core comprises a medicine containing layer and a boosting layer, the semipermeable coating film envelops the tablet core and is provided with medicine release holes, the medicine containing layer contains middle molecular polyoxyethylene (average molecular weight is 900, 000-1, 000,,000) and an osmotic active substance in a certain proportion so that the hydration rate of the medicine containing layer is proper, the release of the active medicine basically presents a progressively-increased release trend and the progressively-increased release can be kept for 14-24 hours by using the bi-layer tablet core and the single-layer coating. By adopting the preparation, the adverse reaction of the medicine can be reduced greatly, the compliance of a patient can be improved, simultaneously, the preparation is simple to prepare, the preparation process of the progressively-increased osmotic pump preparation is simplified greatly, and the preparation is more conductive to industrialized production.

The invention belongs to medical technique field, and relates to osmotic pump controlled-release tablets of alfuzosin hydrochloride and the preparation method, which comprises tablet core, clothing sheet membrane and controlled-release pore. The solid medicine and osmotic active substance and shaping agent forms the tablet core; the coating membrane is insoluble controlled-release clothing sheet that is water permeable but not medical permeable. Said pore is on the clothing sheeting membrane. The comprised raw material of tablet core and clothing sheet membrane and proportion by weight are asfollows: table core: alfuzosin hydrochloride 0.5-50%, packing agent 5-80%, penetration -promoting agent 5-80%, lubricating agent 0.2-3%, adhesive agent 0.01-10%; clothing sheet membrane: semi-permeable membrane clothing sheet high polymer material 70-99%, plasticizing agent 1-30%. The invention is characterized by stable and continuous release, long retention time for effective blood concentration and reduced peak-to-valley of blood concentration phenomena.

The invention discloses an indapamide monolayer osmotic pump sustained-release tablet, which comprises a tablet core and a controlled-release film coating layer, wherein the tablet core contains 0.5-2% of indapamide as a monarch drug, 1-20% of filling agent, 50-90% of penetration enhancer, 1-15% of adhesive, 1-20% of release regulator and 0.5-3% of lubricant; the controlled-release film coating layer comprises a controlled-release film forming material, a plasticizer and / or a pore-forming agent; and the filling agent comprises agar powder.

The invention belongs to the field of medicinal preparation and specifically provides a posaconazole double-layer osmotic pump controlled release tablet and a preparation method thereof. The tablet comprises a tablet core and a semipermeable controlled release film. The tablet core comprises a drug containing layer and a boosting layer. The drug containing layer is located inside the controlled release film which is provided with a drug releasing hole. The boosting layer is located inside the controlled release film at a place far away from the drug releasing hole. One end of the water-permeable controlled release film is provided with one or more drug releasing holes. The release curve of the preparation drug shows a zero-order release pattern, and thus the problem of drug resistance caused by long-term use of posaconazole dosage forms on the market is solved. Besides, the problems that the preparation technology is complex, the preparation cost is high, and the drug is unsuitable for industrialized mass production due to the adoption of a hot-melt extrusion technology are solved. Simultaneously, the in vivo-in vitro correlation of the drug is better ensured and the clinical monitoring of plasma concentration is better facilitated.

The invention discloses a bicyclol double-layer osmotic pump control-released tablet and a preparation method thereof. The preparation, namely the tablet, contains bicyclol and pharmaceutically acceptable auxiliary materials. The structure of the tablet contains two layers of tablet cores, wherein one layer of tablet core is a medicament-containing layer; the other layer of tablet core is a boosting layer; an insoluble semipermeable membrane is wrapped outside the tablet cores; and one or more small medicament-releasing holes are formed on the membrane. The medicament-releasing mechanism of the preparation is novel; the bicyclol medicament is slowly and stably released through an osmotic pressure difference inside and outside the wrapping membrane; the medicament-releasing behavior has good zero-level control-released characteristic and is slightly affected by factors, such as medium environment pH value, gastrointestinal motility, foods and the like; therefore, compared with the ordinary preparation, the preparation provided by the invention can obviously improve the stability of bicyclol blood concentration, reduce the appearance of toxic and side effects and reduce the individual difference of clinical effect.

The present invention provides a drug core composition for controlled-release administration of active drugs with low solubility, which at least includes a drug-containing layer and a booster layer, and the drug-containing layer includes active drugs with low solubility and hydrophilic A polymer carrier, the booster layer at least includes a permeation-promoting polymer, an insoluble polymer and an osmotic pressure enhancer; the present invention also provides an osmotic pump preparation containing the drug core composition, which also includes The thin film of semipermeable material; drug core composition of the present invention can release drug at a controlled rate, so that the formulation containing the drug core composition can release the active drug in about 24 hours once a day. .